Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New US FDA Powers On Rx Abuse Could Be 'Tailored' By Congress, Gottlieb Suggests

Executive Summary

At House hearing on opioid epidemic, FDA Commissioner responds to range of legislative proposals, including those aimed at agency's drug approval and safety monitoring activities.

Advertisement

Related Content

Over-Legislating On Opioids? US FDA May Get New Authorities And Unwanted Tasks
CMS Wants Broader Use of Abuse-Deterrent Opioids – But Needs Help From Congress
Senate Draft Bill On Opioids Tasks US FDA With Clarifying Its Regulation Of New Treatments
Opioids: US Senate Committee Chairman's Discussion Drafts Broadly Reflect FDA Priorities
No Deal: Omnibus Spending Bill Moves Without Part D Discount Relief
Opioid Spotlight: Trump Announces Plans For More Spending As Congress Introduces Two Dozen Bills
Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities
Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling
Curtain Falls On Opana ER As Endo Agrees To US FDA Withdrawal Request

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel